As we continue to see significant advancements in biotechnology innovation, many companies are increasingly shifting their focus to rare diseases — defined by the National Institutes of Health as conditions that impact fewer than 200,000 people in the US.
In total, there are approximately 7,000 to 10,000 known rare diseases, which collectively affect between 25 million and 30 million people across the country according to the NIH While these...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?